Radiopharm Theranostics (RDPTF) Common Equity (2023 - 2026)

Radiopharm Theranostics (RDPTF) has reported Common Equity for 4 consecutive years, with $158353.8 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 42.33% year-over-year to $158353.8 in Q2 2026; TTM through Jun 2026 was $158353.8, a 42.33% decrease from a year earlier, with the FY2026 full-year figure at $151613.5, down 99.65% from the prior year.
• Common Equity was $158353.8 for Q2 2026 at Radiopharm Theranostics, down from $274565.9 in the prior quarter.
• Over five years, Common Equity peaked at $52.0 million in Q4 2024 and troughed at $158353.8 in Q2 2026.
• A 4-year average of $19.6 million and a median of $274565.9 in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 99.6% in 2024 and soared 52.31% in 2025, its largest moves.
• Over 4 years, Common Equity stood at $45.6 million in 2023, then grew by 14.09% to $52.0 million in 2024, then slumped by 99.47% to $274565.9 in 2025, then slumped by 42.33% to $158353.8 in 2026.
• The last three Common Equity figures came in at $158353.8 (Q2 2026), $274565.9 (Q2 2025), and $52.0 million (Q4 2024), per Business Quant data.